BofA downgraded Erasca (ERAS) to Underperform from Buy with a price target of $1.50, down from $4.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca downgraded to Equal Weight from Overweight at Morgan Stanley
- Cautious Outlook on Erasca Due to Strategic Shifts and Delayed Clinical Data
- Erasca’s Strategic Advancements in RAS Programs Justify Buy Rating
- Erasca Reports Progress and Financial Stability in Q2 2025
- Erasca files $500M mixed securities shelf